Neovascular Age-related Macular Degeneration Treatment Market
Neovascular Age-related Macular Degeneration Treatment Market: Global Industry Analysis 2018-2022 and Opportunity Assessment 2023-2033
A recent market study published by FMI on Neovascular Age-related Macular Degeneration Treatment offers a global industry analysis for 2018-2022 and opportunity assessment for 2023-2033. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.
Market Segmentation
By Drug Type:
- Ranibizumab
- Aflibercept
- Bevacizumab
- Brolucizumab
- Faricimab
- Dry AMD
- Wet AMD
- Less than 60
- Between 60 to 80
- More than 80
- Male
- Female
- Early-stage AMD
- Intermediate AMD
- Late-stage AMD
- Hospital Pharmacy
- Specialty Pharmacy
- Online Pharmacy
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Executive Summary
The executive summary of the Neovascular Age-related Macular Degeneration Treatment Market includes the global market outlook, demand side trends, supply side trends and also include FMI analysis and recommendations of Vehicle Radar Test System.
Chapter 01 - Market Overview
Readers can find the detailed segmentation and definition of the Neovascular Age-related Macular Degeneration Treatment Market in this chapter, which will help to understand basic information about Vehicle Radar Test System. This section also highlights the market scope, taxonomy and limitations which help the reader understand the market coverage of Neovascular Age-related Macular Degeneration Treatment Market report.
Chapter 02 - Market Background
This chapter includes detailed analysis of the By Drug Type processing methods overview, consumer buying patterns & tendencies and policy developments and regulatory scenario. It also includes in depth analysis of macro-economic factors and covers topics like global GDP growth outlook, global industry value added, personal consumption, expenditures, modern trade penetration and consumer price indices. The chapter also covers forecast factors - relevance & impact, value chain analysis and market dynamics (drivers, restraints and opportunities) to better understand the market.
Chapter 03 - Global Neovascular Age-related Macular Degeneration Treatment Market Demand Analysis 2018-2022 and Forecast, 2023-2033
The chapter include historical market value (XX) analysis (2018-2022) and current and future market value (US$ 3 billion) and volume (5%) projections (2023-2033). The projections are based on the Y-O-Y growth trend analysis and absolute $ opportunity analysis country of operation.
Chapter 04 - Global Neovascular Age-related Macular Degeneration Treatment Market - Pricing Analysis
Based on By Drug Type, the pricing analysis chapter include Regional pricing analysis (USD/MT), global average pricing analysis benchmark, and key factors impacting the pricing.
Chapter 05 - Global Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Type
Based on By Drug Type, Neovascular Age-related Macular Degeneration Treatment Market is segmented into Ranibizumab, Aflibercept, Bevacizumab, Brolucizumab, Faricimab. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Drug Type.
Chapter 06 - Global Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033, By Disease Type
Based on By Disease Type, Neovascular Age-related Macular Degeneration Treatment Market is segmented into Dry AMD, Wet AMD. This section also offers market attractiveness analysis based on By Disease Type. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Disease Type.
Chapter 07 - Global Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033, By Age Group
Based on By Age Group, Neovascular Age-related Macular Degeneration Treatment Market is segmented into Less than 60, Between 60 to 80, More than 80. This section also offers market attractiveness analysis based on By Age Group. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Age Group.
Chapter 08 - Global Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033, By Gender
Based on By Gender, Neovascular Age-related Macular Degeneration Treatment Market is segmented into Male, Female. This section also offers market attractiveness analysis based on By Gender. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Gender.
Chapter 09 - Global Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033, By Stage of Disease
Based on By Stage of Disease, Neovascular Age-related Macular Degeneration Treatment Market is segmented into Early-stage AMD, Intermediate AMD, Late-stage AMD. This section also offers market attractiveness analysis based on By Stage of Disease. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Stage of Disease.
Chapter 10 - Global Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
Based on By Distribution Channel, Neovascular Age-related Macular Degeneration Treatment Market is segmented into Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy. This section also offers market attractiveness analysis based on By Distribution Channel. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Distribution Channel.
Chapter 11 - Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033, By Region
Based on By Region, Neovascular Age-related Macular Degeneration Treatment Market is segmented into North America, Latin America, Europe, East Asia, South Asia, Oceania and MEA. This section also offers market attractiveness analysis based on By Region. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Region.
Chapter 12 - North America Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033
This chapter includes a detailed analysis of the growth of the Vehicle Radar Test System in the North American region, along with a country-wise assessment that includes the US and Canada. Readers can also find regional trends, regulations, and market growth based on different segment and countries in the North America region.
Chapter 13 - Latin America Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033
This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the Latin America region, along with a country-wise assessment that includes the Brazil, Mexico, Chile, Argentina, Peru and Rest of Latin America. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Neovascular Age-related Macular Degeneration Treatment Market in the Latin America region.
Chapter 14 - Europe Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033
This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the European region, along with a country-wise assessment that includes the Germany, Italy, France, U.K., Spain, Russia, Nordic, Benelux and Rest of Europe. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Neovascular Age-related Macular Degeneration Treatment Market in the regional market.
Chapter 15 - East Asia Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033
This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the East Asia region, along with a country-wise assessment that includes the China, Japan, and South Korea. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Neovascular Age-related Macular Degeneration Treatment Market in the regional market.
Chapter 16 - South Asia Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033
This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the South Asia region, along with a country-wise assessment that includes the India, Indonesia, Malaysia, Thailand, and Rest of South Asia. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Neovascular Age-related Macular Degeneration Treatment Market in the regional market.
Chapter 17 - Middle East and Africa Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033
This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the MEA region, along with a country-wise assessment that includes the GCC Countries, South Africa, North Africa, Turkey and Rest of MEA. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Neovascular Age-related Macular Degeneration Treatment Market in the regional market.
Chapter 18 - Key Countries Neovascular Age-related Macular Degeneration Treatment Market Analysis 2018-2022 and Forecast 2023-2033
This chapter offers insights into how the Neovascular Age-related Macular Degeneration Treatment Market is expected to grow in major countries globally.
Chapter 19 - Market Structure Analysis- Global Assessment
This chapter includes company dashboard, industry structure analysis by tier of companies, 2022E, company share analysis of top players, 2022E, and competition benchmarking- matrix.
Chapter 20 - Competition Deep Dive (Tentative List)
This chapter includes company overview, By Drug Type portfolio of companies, profitability by market segments, sales footprint, SWOT analysis and strategy overview of the companies being studied in the report. Some of the market players featured in the report are F. Hoffmann- La Roche AG, Bausch + Lomb, Novartis AG, Pfizer Inc., Allergan Plc., Acucela Inc., Santen Pharmaceuticals Co., Ophthotech Corporation, Alimera Sciences Inc., GSK plc., Regeneron Pharmaceuticals Inc., Bayer AG, RXi Pharmaceuticals Inc.
Chapter 21 - Assumptions and Acronyms
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the Vehicle Radar Test System report.
Chapter 22 - Research Methodology
This chapter helps readers understand the research methodology followed to obtain various conclusions, as well as important qualitative and quantitative information, on Neovascular Age-related Macular Degeneration Treatment Market.
- 1. Executive Summary | Neovascular Age-related Macular Degeneration Treatment Market
- 1.1. Global Market Outlook
- 1.2. Demand-side Trends
- 1.3. Supply-side Trends
- 1.4. Technology Roadmap Analysis
- 1.5. Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 3. Market Background
- 3.1. Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Restraints
- 3.1.3. Opportunity
- 3.1.4. Trends
- 3.2. Scenario Forecast
- 3.2.1. Demand in Optimistic Scenario
- 3.2.2. Demand in Likely Scenario
- 3.2.3. Demand in Conservative Scenario
- 3.3. Opportunity Map Analysis
- 3.4. Investment Feasibility Matrix
- 3.5. PESTLE and Porter’s Analysis
- 3.6. Regulatory Landscape
- 3.6.1. By Key Regions
- 3.6.2. By Key Countries
- 3.7. Regional Parent Market Outlook
- 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
- 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
- 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
- 4.2.1. Y-o-Y Growth Trend Analysis
- 4.2.2. Absolute $ Opportunity Analysis
- 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
- 5.1. Introduction / Key Findings
- 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022
- 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
- 5.3.1. Ranibizumab
- 5.3.2. Aflibercept
- 5.3.3. Bevacizumab
- 5.3.4. Brolucizumab
- 5.3.5. Faricimab
- 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
- 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
- 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type
- 6.1. Introduction / Key Findings
- 6.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022
- 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033
- 6.3.1. Dry AMD
- 6.3.2. Wet AMD
- 6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022
- 6.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033
- 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age Group
- 7.1. Introduction / Key Findings
- 7.2. Historical Market Size Value (US$ Million) Analysis By Age Group , 2018 to 2022
- 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Age Group , 2023 to 2033
- 7.3.1. Less Than 60
- 7.3.2. Between 60 to 80
- 7.3.3. More Than 80
- 7.4. Y-o-Y Growth Trend Analysis By Age Group , 2018 to 2022
- 7.5. Absolute $ Opportunity Analysis By Age Group , 2023 to 2033
- 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Gender
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size Value (US$ Million) Analysis By Gender, 2018 to 2022
- 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Gender, 2023 to 2033
- 8.3.1. Male
- 8.3.2. Female
- 8.4. Y-o-Y Growth Trend Analysis By Gender, 2018 to 2022
- 8.5. Absolute $ Opportunity Analysis By Gender, 2023 to 2033
- 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Stage of Disease
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size Value (US$ Million) Analysis By Stage of Disease, 2018 to 2022
- 9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Stage of Disease, 2023 to 2033
- 9.3.1. Early-stage AMD
- 9.3.2. Intermediate AMD
- 9.3.3. Late-stage AMD
- 9.4. Y-o-Y Growth Trend Analysis By Stage of Disease, 2018 to 2022
- 9.5. Absolute $ Opportunity Analysis By Stage of Disease, 2023 to 2033
- 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
- 10.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
- 10.3.1. Hospital Pharmacy
- 10.3.2. Specialty Pharmacy
- 10.3.3. Online Pharmacy
- 10.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
- 10.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
- 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
- 11.1. Introduction
- 11.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
- 11.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
- 11.3.1. North America
- 11.3.2. Latin America
- 11.3.3. Europe
- 11.3.4. South Asia
- 11.3.5. East Asia
- 11.3.6. Oceania
- 11.3.7. MEA
- 11.4. Market Attractiveness Analysis By Region
- 12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
- 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
- 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
- 12.2.1. By Country
- 12.2.1.1. United States
- 12.2.1.2. Canada
- 12.2.2. By Drug Type
- 12.2.3. By Disease Type
- 12.2.4. By Age Group
- 12.2.5. By Gender
- 12.2.6. By Stage of Disease
- 12.2.7. By Distribution Channel
- 12.3. Market Attractiveness Analysis
- 12.3.1. By Country
- 12.3.2. By Drug Type
- 12.3.3. By Disease Type
- 12.3.4. By Age Group
- 12.3.5. By Gender
- 12.3.6. By Stage of Disease
- 12.3.7. By Distribution Channel
- 12.4. Key Takeaways
- 13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
- 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
- 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
- 13.2.1. By Country
- 13.2.1.1. Brazil
- 13.2.1.2. Mexico
- 13.2.1.3. Rest of Latin America
- 13.2.2. By Drug Type
- 13.2.3. By Disease Type
- 13.2.4. By Age Group
- 13.2.5. By Gender
- 13.2.6. By Stage of Disease
- 13.2.7. By Distribution Channel
- 13.3. Market Attractiveness Analysis
- 13.3.1. By Country
- 13.3.2. By Drug Type
- 13.3.3. By Disease Type
- 13.3.4. By Age Group
- 13.3.5. By Gender
- 13.3.6. By Stage of Disease
- 13.3.7. By Distribution Channel
- 13.4. Key Takeaways
- 14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
- 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
- 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
- 14.2.1. By Country
- 14.2.1.1. Germany
- 14.2.1.2. United Kingdom
- 14.2.1.3. France
- 14.2.1.4. Spain
- 14.2.1.5. Italy
- 14.2.1.6. Rest of Europe
- 14.2.2. By Drug Type
- 14.2.3. By Disease Type
- 14.2.4. By Age Group
- 14.2.5. By Gender
- 14.2.6. By Stage of Disease
- 14.2.7. By Distribution Channel
- 14.3. Market Attractiveness Analysis
- 14.3.1. By Country
- 14.3.2. By Drug Type
- 14.3.3. By Disease Type
- 14.3.4. By Age Group
- 14.3.5. By Gender
- 14.3.6. By Stage of Disease
- 14.3.7. By Distribution Channel
- 14.4. Key Takeaways
- 15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
- 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
- 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
- 15.2.1. By Country
- 15.2.1.1. India
- 15.2.1.2. Malaysia
- 15.2.1.3. Singapore
- 15.2.1.4. Thailand
- 15.2.1.5. Rest of South Asia
- 15.2.2. By Drug Type
- 15.2.3. By Disease Type
- 15.2.4. By Age Group
- 15.2.5. By Gender
- 15.2.6. By Stage of Disease
- 15.2.7. By Distribution Channel
- 15.3. Market Attractiveness Analysis
- 15.3.1. By Country
- 15.3.2. By Drug Type
- 15.3.3. By Disease Type
- 15.3.4. By Age Group
- 15.3.5. By Gender
- 15.3.6. By Stage of Disease
- 15.3.7. By Distribution Channel
- 15.4. Key Takeaways
- 16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
- 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
- 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
- 16.2.1. By Country
- 16.2.1.1. China
- 16.2.1.2. Japan
- 16.2.1.3. South Korea
- 16.2.2. By Drug Type
- 16.2.3. By Disease Type
- 16.2.4. By Age Group
- 16.2.5. By Gender
- 16.2.6. By Stage of Disease
- 16.2.7. By Distribution Channel
- 16.3. Market Attractiveness Analysis
- 16.3.1. By Country
- 16.3.2. By Drug Type
- 16.3.3. By Disease Type
- 16.3.4. By Age Group
- 16.3.5. By Gender
- 16.3.6. By Stage of Disease
- 16.3.7. By Distribution Channel
- 16.4. Key Takeaways
- 17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
- 17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
- 17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
- 17.2.1. By Country
- 17.2.1.1. Australia
- 17.2.1.2. New Zealand
- 17.2.2. By Drug Type
- 17.2.3. By Disease Type
- 17.2.4. By Age Group
- 17.2.5. By Gender
- 17.2.6. By Stage of Disease
- 17.2.7. By Distribution Channel
- 17.3. Market Attractiveness Analysis
- 17.3.1. By Country
- 17.3.2. By Drug Type
- 17.3.3. By Disease Type
- 17.3.4. By Age Group
- 17.3.5. By Gender
- 17.3.6. By Stage of Disease
- 17.3.7. By Distribution Channel
- 17.4. Key Takeaways
- 18. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
- 18.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
- 18.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
- 18.2.1. By Country
- 18.2.1.1. GCC Countries
- 18.2.1.2. South Africa
- 18.2.1.3. Israel
- 18.2.1.4. Rest of MEA
- 18.2.2. By Drug Type
- 18.2.3. By Disease Type
- 18.2.4. By Age Group
- 18.2.5. By Gender
- 18.2.6. By Stage of Disease
- 18.2.7. By Distribution Channel
- 18.3. Market Attractiveness Analysis
- 18.3.1. By Country
- 18.3.2. By Drug Type
- 18.3.3. By Disease Type
- 18.3.4. By Age Group
- 18.3.5. By Gender
- 18.3.6. By Stage of Disease
- 18.3.7. By Distribution Channel
- 18.4. Key Takeaways
- 19. Key Countries Market Analysis
- 19.1. U.S.
- 19.1.1. Pricing Analysis
- 19.1.2. Market Share Analysis, 2022
- 19.1.2.1. By Drug Type
- 19.1.2.2. By Disease Type
- 19.1.2.3. By Age Group
- 19.1.2.4. By Gender
- 19.1.2.5. By Stage of Disease
- 19.1.2.6. By Distribution Channel
- 19.2. Canada
- 19.2.1. Pricing Analysis
- 19.2.2. Market Share Analysis, 2022
- 19.2.2.1. By Drug Type
- 19.2.2.2. By Disease Type
- 19.2.2.3. By Age Group
- 19.2.2.4. By Gender
- 19.2.2.5. By Stage of Disease
- 19.2.2.6. By Distribution Channel
- 19.3. Brazil
- 19.3.1. Pricing Analysis
- 19.3.2. Market Share Analysis, 2022
- 19.3.2.1. By Drug Type
- 19.3.2.2. By Disease Type
- 19.3.2.3. By Age Group
- 19.3.2.4. By Gender
- 19.3.2.5. By Stage of Disease
- 19.3.2.6. By Distribution Channel
- 19.4. Mexico
- 19.4.1. Pricing Analysis
- 19.4.2. Market Share Analysis, 2022
- 19.4.2.1. By Drug Type
- 19.4.2.2. By Disease Type
- 19.4.2.3. By Age Group
- 19.4.2.4. By Gender
- 19.4.2.5. By Stage of Disease
- 19.4.2.6. By Distribution Channel
- 19.5. Germany
- 19.5.1. Pricing Analysis
- 19.5.2. Market Share Analysis, 2022
- 19.5.2.1. By Drug Type
- 19.5.2.2. By Disease Type
- 19.5.2.3. By Age Group
- 19.5.2.4. By Gender
- 19.5.2.5. By Stage of Disease
- 19.5.2.6. By Distribution Channel
- 19.6. U.K.
- 19.6.1. Pricing Analysis
- 19.6.2. Market Share Analysis, 2022
- 19.6.2.1. By Drug Type
- 19.6.2.2. By Disease Type
- 19.6.2.3. By Age Group
- 19.6.2.4. By Gender
- 19.6.2.5. By Stage of Disease
- 19.6.2.6. By Distribution Channel
- 19.7. France
- 19.7.1. Pricing Analysis
- 19.7.2. Market Share Analysis, 2022
- 19.7.2.1. By Drug Type
- 19.7.2.2. By Disease Type
- 19.7.2.3. By Age Group
- 19.7.2.4. By Gender
- 19.7.2.5. By Stage of Disease
- 19.7.2.6. By Distribution Channel
- 19.8. Spain
- 19.8.1. Pricing Analysis
- 19.8.2. Market Share Analysis, 2022
- 19.8.2.1. By Drug Type
- 19.8.2.2. By Disease Type
- 19.8.2.3. By Age Group
- 19.8.2.4. By Gender
- 19.8.2.5. By Stage of Disease
- 19.8.2.6. By Distribution Channel
- 19.9. Italy
- 19.9.1. Pricing Analysis
- 19.9.2. Market Share Analysis, 2022
- 19.9.2.1. By Drug Type
- 19.9.2.2. By Disease Type
- 19.9.2.3. By Age Group
- 19.9.2.4. By Gender
- 19.9.2.5. By Stage of Disease
- 19.9.2.6. By Distribution Channel
- 19.10. India
- 19.10.1. Pricing Analysis
- 19.10.2. Market Share Analysis, 2022
- 19.10.2.1. By Drug Type
- 19.10.2.2. By Disease Type
- 19.10.2.3. By Age Group
- 19.10.2.4. By Gender
- 19.10.2.5. By Stage of Disease
- 19.10.2.6. By Distribution Channel
- 19.11. Malaysia
- 19.11.1. Pricing Analysis
- 19.11.2. Market Share Analysis, 2022
- 19.11.2.1. By Drug Type
- 19.11.2.2. By Disease Type
- 19.11.2.3. By Age Group
- 19.11.2.4. By Gender
- 19.11.2.5. By Stage of Disease
- 19.11.2.6. By Distribution Channel
- 19.12. Singapore
- 19.12.1. Pricing Analysis
- 19.12.2. Market Share Analysis, 2022
- 19.12.2.1. By Drug Type
- 19.12.2.2. By Disease Type
- 19.12.2.3. By Age Group
- 19.12.2.4. By Gender
- 19.12.2.5. By Stage of Disease
- 19.12.2.6. By Distribution Channel
- 19.13. Thailand
- 19.13.1. Pricing Analysis
- 19.13.2. Market Share Analysis, 2022
- 19.13.2.1. By Drug Type
- 19.13.2.2. By Disease Type
- 19.13.2.3. By Age Group
- 19.13.2.4. By Gender
- 19.13.2.5. By Stage of Disease
- 19.13.2.6. By Distribution Channel
- 19.14. China
- 19.14.1. Pricing Analysis
- 19.14.2. Market Share Analysis, 2022
- 19.14.2.1. By Drug Type
- 19.14.2.2. By Disease Type
- 19.14.2.3. By Age Group
- 19.14.2.4. By Gender
- 19.14.2.5. By Stage of Disease
- 19.14.2.6. By Distribution Channel
- 19.15. Japan
- 19.15.1. Pricing Analysis
- 19.15.2. Market Share Analysis, 2022
- 19.15.2.1. By Drug Type
- 19.15.2.2. By Disease Type
- 19.15.2.3. By Age Group
- 19.15.2.4. By Gender
- 19.15.2.5. By Stage of Disease
- 19.15.2.6. By Distribution Channel
- 19.16. South Korea
- 19.16.1. Pricing Analysis
- 19.16.2. Market Share Analysis, 2022
- 19.16.2.1. By Drug Type
- 19.16.2.2. By Disease Type
- 19.16.2.3. By Age Group
- 19.16.2.4. By Gender
- 19.16.2.5. By Stage of Disease
- 19.16.2.6. By Distribution Channel
- 19.17. Australia
- 19.17.1. Pricing Analysis
- 19.17.2. Market Share Analysis, 2022
- 19.17.2.1. By Drug Type
- 19.17.2.2. By Disease Type
- 19.17.2.3. By Age Group
- 19.17.2.4. By Gender
- 19.17.2.5. By Stage of Disease
- 19.17.2.6. By Distribution Channel
- 19.18. New Zealand
- 19.18.1. Pricing Analysis
- 19.18.2. Market Share Analysis, 2022
- 19.18.2.1. By Drug Type
- 19.18.2.2. By Disease Type
- 19.18.2.3. By Age Group
- 19.18.2.4. By Gender
- 19.18.2.5. By Stage of Disease
- 19.18.2.6. By Distribution Channel
- 19.19. GCC Countries
- 19.19.1. Pricing Analysis
- 19.19.2. Market Share Analysis, 2022
- 19.19.2.1. By Drug Type
- 19.19.2.2. By Disease Type
- 19.19.2.3. By Age Group
- 19.19.2.4. By Gender
- 19.19.2.5. By Stage of Disease
- 19.19.2.6. By Distribution Channel
- 19.20. South Africa
- 19.20.1. Pricing Analysis
- 19.20.2. Market Share Analysis, 2022
- 19.20.2.1. By Drug Type
- 19.20.2.2. By Disease Type
- 19.20.2.3. By Age Group
- 19.20.2.4. By Gender
- 19.20.2.5. By Stage of Disease
- 19.20.2.6. By Distribution Channel
- 19.21. Israel
- 19.21.1. Pricing Analysis
- 19.21.2. Market Share Analysis, 2022
- 19.21.2.1. By Drug Type
- 19.21.2.2. By Disease Type
- 19.21.2.3. By Age Group
- 19.21.2.4. By Gender
- 19.21.2.5. By Stage of Disease
- 19.21.2.6. By Distribution Channel
- 20. Market Structure Analysis
- 20.1. Competition Dashboard
- 20.2. Competition Benchmarking
- 20.3. Market Share Analysis of Top Players
- 20.3.1. By Regional
- 20.3.2. By Drug Type
- 20.3.3. By Disease Type
- 20.3.4. By Age Group
- 20.3.5. By Gender
- 20.3.6. By Stage of Disease
- 20.3.7. By Distribution Channel
- 21. Competition Analysis
- 21.1. Competition Deep Dive
- 21.1.1. F.Hoffmann-La Roche AG
- 21.1.1.1. Overview
- 21.1.1.2. Product Portfolio
- 21.1.1.3. Profitability by Market Segments
- 21.1.1.4. Sales Footprint
- 21.1.1.5. Strategy Overview
- 21.1.1.5.1. Marketing Strategy
- 21.1.2. Bausch + Lomb
- 21.1.2.1. Overview
- 21.1.2.2. Product Portfolio
- 21.1.2.3. Profitability by Market Segments
- 21.1.2.4. Sales Footprint
- 21.1.2.5. Strategy Overview
- 21.1.2.5.1. Marketing Strategy
- 21.1.3. Novartis AG
- 21.1.3.1. Overview
- 21.1.3.2. Product Portfolio
- 21.1.3.3. Profitability by Market Segments
- 21.1.3.4. Sales Footprint
- 21.1.3.5. Strategy Overview
- 21.1.3.5.1. Marketing Strategy
- 21.1.4. Pfizer Inc.
- 21.1.4.1. Overview
- 21.1.4.2. Product Portfolio
- 21.1.4.3. Profitability by Market Segments
- 21.1.4.4. Sales Footprint
- 21.1.4.5. Strategy Overview
- 21.1.4.5.1. Marketing Strategy
- 21.1.5. Allergan Plc.
- 21.1.5.1. Overview
- 21.1.5.2. Product Portfolio
- 21.1.5.3. Profitability by Market Segments
- 21.1.5.4. Sales Footprint
- 21.1.5.5. Strategy Overview
- 21.1.5.5.1. Marketing Strategy
- 21.1.6. Acucela Inc.
- 21.1.6.1. Overview
- 21.1.6.2. Product Portfolio
- 21.1.6.3. Profitability by Market Segments
- 21.1.6.4. Sales Footprint
- 21.1.6.5. Strategy Overview
- 21.1.6.5.1. Marketing Strategy
- 21.1.7. Santen Pharmaceuticals Co.
- 21.1.7.1. Overview
- 21.1.7.2. Product Portfolio
- 21.1.7.3. Profitability by Market Segments
- 21.1.7.4. Sales Footprint
- 21.1.7.5. Strategy Overview
- 21.1.7.5.1. Marketing Strategy
- 21.1.8. Ophthotech Corporation
- 21.1.8.1. Overview
- 21.1.8.2. Product Portfolio
- 21.1.8.3. Profitability by Market Segments
- 21.1.8.4. Sales Footprint
- 21.1.8.5. Strategy Overview
- 21.1.8.5.1. Marketing Strategy
- 21.1.9. Alimera Sciences Inc.
- 21.1.9.1. Overview
- 21.1.9.2. Product Portfolio
- 21.1.9.3. Profitability by Market Segments
- 21.1.9.4. Sales Footprint
- 21.1.9.5. Strategy Overview
- 21.1.9.5.1. Marketing Strategy
- 21.1.10. GSK plc.
- 21.1.10.1. Overview
- 21.1.10.2. Product Portfolio
- 21.1.10.3. Profitability by Market Segments
- 21.1.10.4. Sales Footprint
- 21.1.10.5. Strategy Overview
- 21.1.10.5.1. Marketing Strategy
- 21.1.11. Regeneron Pharmaceuticals Inc.
- 21.1.11.1. Overview
- 21.1.11.2. Product Portfolio
- 21.1.11.3. Profitability by Market Segments
- 21.1.11.4. Sales Footprint
- 21.1.11.5. Strategy Overview
- 21.1.11.5.1. Marketing Strategy
- 21.1.12. Bayer AG
- 21.1.12.1. Overview
- 21.1.12.2. Product Portfolio
- 21.1.12.3. Profitability by Market Segments
- 21.1.12.4. Sales Footprint
- 21.1.12.5. Strategy Overview
- 21.1.12.5.1. Marketing Strategy
- 21.1.13. RXi Pharmaceuticals Inc.
- 21.1.13.1. Overview
- 21.1.13.2. Product Portfolio
- 21.1.13.3. Profitability by Market Segments
- 21.1.13.4. Sales Footprint
- 21.1.13.5. Strategy Overview
- 21.1.13.5.1. Marketing Strategy
- 22. Assumptions & Acronyms Used
- 23. Research Methodology
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook